UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV
18 nov. 2014 05h44 HE
|
Bionor Pharma
OSLO, NORWAY--(Marketwired - Nov 18, 2014) - Bionor Pharma ASA (OSLO: BIONOR)
Treatment with Vacc-4x + Revlimid (lenalidomide) was well tolerated
...
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV
17 nov. 2014 08h01 HE
|
Bionor Pharma
OSLO, NORWAY--(Marketwired - Nov 17, 2014) - Bionor Pharma ASA (OSLO: BIONOR)
Treatment with Vacc-4x + Revlimid (lenalidomide) was safe and well tolerated
...
Bionor Pharma's Phase II Vacc-4x Data Published in the Lancet Infectious Diseases
11 févr. 2014 09h27 HE
|
Bionor Pharma
OSLO, NORWAY--(Marketwired - Feb 11, 2014) - Bionor Pharma ASA (OSE: BIONOR) announces that the results from the randomized, multicenter, double-blinded, placebo-controlled Phase II trial with 135...
International Patent Application Submitted for the Therapeutic and Potentially Preventive Vaccine Vacc-HIV, Combining Bionor's Vacc-4x and Vacc-C5
07 juin 2012 07h01 HE
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - Jun 7, 2012) - Bionor Pharma ASA (OSLO: BIONOR) announced today that it has initiated the international patent process for protection of the Company's peptide vaccine...
International Patent Application Submitted Covering Vaccines for Influenza (Universal Vaccine), Hepatitis C, Cytomegalovirus and Human Papillomavirus
07 juin 2012 07h00 HE
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - Jun 7, 2012) - Bionor Pharma ASA (OSLO: BIONOR)
News Summary
The new patent filed 6 June aims to strengthen the Company's general protection of its...
First Human Clinical Study of HIV Vaccine Vacc-C5 Approved to Begin
29 mai 2012 11h22 HE
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - May 29, 2012) - Bionor Pharma ASA (OSLO: BIONOR)
News Summary
Open, clinical study, dose escalating, phase I/II, with Bionor...
Bionor Pharma's Shareholders Voted Industry Experts Steen Kroyer, Jerry Zeldis and Benedicte Fossum to Its Board of Directors at Annual General Meeting
11 mai 2012 08h52 HE
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - May 11, 2012) - Bionor Pharma ASA (OSLO: BIONOR) announced today unanimously shareholder approval for new and re-elected Board members to the Board of Directors, and...
Successful Immunization and Safety Documented in Nasal Administration Study of the HIV Vaccine Vacc-4x Together With Endocine
10 mai 2012 06h47 HE
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - May 10, 2012) - Bionor Pharma (OSLO: BIONOR)
News Summary
Vaccine related immune responses found in HIV patients given Vacc-4x...
With Final Review of Phase IIb Viral Load Data Completed, Researchers Confirm Statistically Significant Reduction of HIV Viral Load on Vacc-4x Compared to Placebo
15 févr. 2012 08h00 HE
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - Feb 15, 2012) - Bionor Pharma (OSLO: BIONOR)
News Summary
Final review of phase IIb data confirms statistically significant 64%...
With Final Documentation Submitted for International Patent Applications, Bionor Sees Promise of Two Core Platform Technologies
23 janv. 2012 08h00 HE
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - Jan 23, 2012) -
News Summary
Bionor Pharma ASA has previously submitted two international patent applications for the Company's...